Neovasc Maintains Investor Confidence Despite FDA Struggles; Sells $72M In Stock
Executive Summary
Despite a recent unfavorable FDA advisory panel for its Reducer coronary sinus device, some investors showed their faith in the Canadian company by buying 36 million shares.
You may also be interested in...
Neovasc Plans Next Steps After Thumbs Down From FDA Panel
FDA advisory committee members said the trial population was too small and homogenous and did not establish that Neovasc’s Reducer effectively treats angina.
Starts & Stops: Neovasc Reports Progress On TIARA-II Trial Of Transcatheter Mitral Valve
Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by MedDeviceTracker. This edition covers trial announcements from Jan. 28 through Feb. 4, including announcements from Neovasc, NaturalCycles Nordic, and Elekta.
JPM 2022: Abiomed, Penumbra, Renalityx
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the fourth day of the meeting.